> > Diagnosis Codes

Diagnosis codes for coagulation disorders.

Claim forms typically require an International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) or Tenth Revision (ICD-10-CM) diagnosis code.

It may be appropriate to use one of the diagnosis codes below for patients treated with NovoSeven® RT.

Hemophilia A (FVIII deficiency)

ICD-9-CM1       ICD-10-CM2

286.0                 D66

Hemophilia B (FIX deficiency)

ICD-9-CM1       ICD-10-CM2
286.1                 D67

Other hereditary factor deficiencies (including FVII deficiency)

ICD-9-CM1       ICD-10-CM2

286.3                D68.2

Acquired hemophilia

ICD-9-CM1       ICD-10-CM2

286.52            D68.311

Other hemorrhagic disorder due to intrinsic circulation anticoagulants, antibodies, or inhibitors

ICD-9-CM1       ICD-10-CM2

286.59            D68.318

Glanzmann's thrombasthenia
(listed under "Qualitative Platelet Defects")

ICD-9-CM1       ICD-10-CM2

287.1                 D69.1

NovoSeven® RT Infusion Code

J code3

J7189

J code3                   J7189

Have a question? We’re

here to help.

Find a representative

How to order

NovoSeven® RT.

See authorized trading partners

Interested in acquired

hemophilia?

Learn to spot the signs

Available from Novo Nordisk:

Visit website | Prescribing Information

Visit website | Prescribing Information

Visit website | Prescribing Information

Selected Important Safety Information

WARNING: THROMBOSIS

  • Serious arterial and venous thrombotic events following administration of NovoSeven® RT have been reported.
  • Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive NovoSeven® RT.
  • Monitor patients for signs or symptoms of activation of the coagulation system and for thrombosis.

Indications and Usage

NovoSeven® RT (Coagulation Factor VIIa [Recombinant]) is a coagulation factor indicated for:

  • Treatment of bleeding episodes and peri-operative management in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and Glanzmann’s thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets
  • Treatment of bleeding episodes and peri-operative management in adults with acquired hemophilia

 

Important Safety Information

WARNING: THROMBOSIS

  • Serious arterial and venous thrombotic events following administration of NovoSeven® RT have been reported.
  • Discuss the risks and explain the signs and symptoms of thrombotic and thromboembolic events to patients who will receive NovoSeven® RT.
  • Monitor patients for signs or symptoms of activation of the coagulation system and for thrombosis.

Warnings and Precautions

  • Serious arterial and venous thrombotic events have been reported in clinical trials and postmarketing surveillance.
  • Exercise caution when administering NovoSeven® RT to patients with an increased risk of thromboembolic complications, such as those with disseminated intravascular coagulation (DIC), advanced atherosclerotic disease, crush injury, septicemia, uncontrolled post-partum hemorrhage, history of coronary heart disease, liver disease, post-operative immobilization, in elderly patients, in neonates, or in patients receiving concomitant treatment with aPCCs/PCCs (activated or nonactivated prothrombin complex concentrates).
  • Hypersensitivity reactions, including anaphylaxis, have been reported with NovoSeven® RT. Administer only if clearly needed in patients with known hypersensitivity to NovoSeven® RT, any of its components, or mouse, hamster, or bovine proteins. Should symptoms occur, discontinue NovoSeven® RT and administer appropriate treatment.
  • Factor VII deficient patients should be monitored for prothrombin time (PT) and factor VII coagulant activity (FVII:C). If FVII:C fails to reach the expected level, or PT is not corrected, or bleeding is not controlled after treatment with the recommended doses, antibody formation may be suspected and analysis for antibodies should be performed.
  • Laboratory coagulation parameters (PT/INR, aPTT, FVII:C) have shown no direct correlation to achieving hemostasis.

Adverse Reactions

  • The most common and serious adverse reactions in clinical trials are thrombotic events. Thrombotic adverse reactions following the administration of NovoSeven® RT in clinical trials occurred in 4% of patients with acquired hemophilia and 0.2% of bleeding episodes in patients with congenital hemophilia.

Drug Interactions

  • Thrombosis may occur if NovoSeven® RT is administered concomitantly with Coagulation Factor XIII.

Please click here for Prescribing Information.  

 

References:

  1. Centers for Disease Control and Prevention. International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). ftp://ftp.cdc.gov/pub/Health_Statistics/NICHS/Publications/ICD9-CM2011/. Updated June 18, 2013. Accessed December 10, 2015.
  2. Centers for Disease Control and Prevention. International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM). http://www.cdc.gov/nchs/icd/icd10cm.htm#icd2016. Updated October 29, 2015. Accessed January 8, 2016.
  3. Centers for Medicare & Medicaid Services, 2015 HCPCS alpha-numeric index.  
    https://www.cms.gov/medicare/coding/medhcpcsgeninfo/index.html. Accessed January 8, 2016.